002720 — Kukje Pharma Co Income Statement
0.000.00%
- KR₩101bn
- KR₩122bn
- KR₩135bn
Annual income statement for Kukje Pharma Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 111,122 | 130,395 | 119,746 | 126,583 | 135,373 |
Cost of Revenue | |||||
Gross Profit | 52,985 | 64,805 | 54,470 | 63,254 | 67,225 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 105,598 | 124,322 | 121,425 | 121,787 | 139,229 |
Operating Profit | 5,524 | 6,073 | -1,679 | 4,797 | -3,856 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 121 | 5,594 | -1,110 | 4,745 | -6,681 |
Provision for Income Taxes | |||||
Net Income After Taxes | -4,762 | 2,195 | -1,556 | 3,543 | -8,415 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -4,761 | 2,203 | -1,559 | 3,557 | -8,415 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -4,761 | 2,203 | -1,559 | 3,557 | -8,415 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -234 | 99.8 | -76.6 | 193 | -365 |
Dividends per Share |